Combined Treatments for Metastatic Prostate Cancer
Onur Alkan (Author), Sinan Koca (Author)
Release Date: 2024-06-19
Combining treatments in prostate cancer is crucial for improving patient outcomes. This approach can include surgery, radiation therapy, hormone therapy, and chemotherapy, tailored to the individual’s specific condition. By targeting the cancer in multiple ways, the likelihood of controlling the disease increases. Additionally, combination therapies can help reduce the risk of recurrence and manage symptoms [...]
Media Type
Buy from
Price may vary by retailers
Work Type | Book Chapter |
---|---|
Published in | Current Management of Metastatic Prostate Cancer |
First Page | 121 |
Last Page | 129 |
DOI | https://doi.org/10.69860/nobel.9786053359142.12 |
Page Count | 9 |
Copyright Holder | Nobel Tıp Kitabevleri |
License | https://nobelpub.com/publish-with-us/copyright-and-licensing |
Onur Alkan (Author)
MD, Istanbul Medeniyet University
https://orcid.org/0000-0002-8558-1654
3Onur Alkan is a Medical Oncology Fellow in his first year. He is interested in prostate cancer and trains at the Medical Oncology Clinic of Medeniyet University Hospital, where many patients with metastatic prostate cancer are treated, alongside Professor Mahmut Gumus. He closely follows the literature on prostate cancer and works as a sub-investigator in some clinical trials at this topic.
Sinan Koca (Author)
MD, Istanbul Medeniyet University
https://orcid.org/0000-0002-8370-1587
3Sinan Koca is a Medical Oncology Associate Professor. His main area of interest is genitourinary cancers, in which he is an expert. He has publications in numerous high-impact factor journals. Additionally, he has held many positions such as the member of the Turkish Medical Oncology Association. He currently continues his activities as the member of the Medical Oncology Clinic at Medeniyet University
Sweeney CJ, Chen YH, Carducci M, Liu G, Jarrard DF, Eisenberger M, et al. Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer. New England Journal of Medicine. 2015;373(8):737–46.
Parker CC, James ND, Brawley CD, Clarke NW, Hoyle AP, Ali A, et al. Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial. The Lancet. 2018;392(10162):2353–66.
Fizazi K, Tran N, Fein L, Matsubara N, Rodriguez-Antolin A, Alekseev BY, et al. Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer. New England Journal of Medicine. 2017;377(4):352–60.
Chi KN, Agarwal N, Bjartell A, Chung BH, Pereira de Santana Gomes AJ, Given R, et al. Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer. New England Journal of Medicine. 2019;381(1):13–24.
Davis ID, Martin AJ, Stockler MR, Begbie S, Chi KN, Chowdhury S, et al. Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer. New England Journal of Medicine. 2019;381(2):121–31.
Armstrong AJ, Szmulewitz RZ, Petrylak DP, Holzbeierlein J, Villers A, Azad A, et al. ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate Cancer. Journal of Clinical Oncology. 2019;37(32):2974–86.
Smith MR, Hussain M, Saad F, Fizazi K, Sternberg CN, Crawford ED, et al. Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer. New England Journal of Medicine. 2022;386(12):1132–42.
Freedland SJ, de Almeida Luz M, De Giorgi U, Gleave M, Gotto GT, Pieczonka CM, et al. Improved Outcomes with Enzalutamide in Biochemically Recurrent Prostate Cancer. New England Journal of Medicine. 2023;389(16):1453–65.
Fizazi K, Foulon S, Carles J, Roubaud G, McDermott R, Fléchon A, et al. Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2×2 factorial design. The Lancet. 2022;399(10336):1695–707.
Burdett S, Boevé LM, Ingleby FC, Fisher DJ, Rydzewska LH, Vale CL, et al. Prostate Radiotherapy for Metastatic Hormone-sensitive Prostate Cancer: A STOPCAP Systematic Review and Meta-analysis. Eur Urol. 2019;76(1):115–24.
Saad F, Clarke NW, Oya M, Shore N, Procopio G, Guedes JD, et al. Olaparib plus abiraterone versus placebo plus abiraterone in metastatic castration-resistant prostate cancer (PROpel): final prespecified overall survival results of a randomised, double-blind, phase 3 trial. Lancet Oncol. 2023;24(10):1094–108.
Chi KN, Sandhu S, Smith MR, Attard G, Saad M, Olmos D, et al. Niraparib plus abiraterone acetate with prednisone in patients with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations: second interim analysis of the randomized phase III MAGNITUDE trial. Annals of Oncology. 2023;34(9):772–82.
de Bono J, Mateo J, Fizazi K, Saad F, Shore N, Sandhu S, et al. Olaparib for Metastatic Castration-Resistant Prostate Cancer. New England Journal of Medicine. 2020;382(22):2091–102.
Agarwal N, Azad AA, Carles J, Fay AP, Matsubara N, Heinrich D, et al. Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial. The Lancet. 2023;402(10398):291–303.
Hussain MHA, Kocherginsky M, Agarwal N, Adra N, Zhang J, Paller CJ, et al. BRCAAway: A randomized phase 2 trial of abiraterone, olaparib, or abiraterone + olaparib in patients with metastatic castration-resistant prostate cancer (mCRPC) bearing homologous recombination-repair mutations (HRRm). Journal of Clinical Oncology. 2024;42(4_suppl):19–19.
Emmett L, Subramaniam S, Crumbaker M, Joshua AM, Weickhardt AJ, Lee ST, et al. LBA84 Enzalutamide and 177Lu-PSMA-617 in poor-risk, metastatic, castration-resistant prostate cancer (mCRPC): A randomised, phase II trial: ENZA-p (ANZUP 1901). Annals of Oncology. 2023 Oct;34:S1325.
Sweeney C, Bracarda S, Sternberg CN, Chi KN, Olmos D, Sandhu S, et al. Ipatasertib plus abiraterone and prednisolone in metastatic castration-resistant prostate cancer (IPATential150): a multicentre, randomised, double-blind, phase 3 trial. The Lancet. 2021;398(10295):131–42.
Ryan CJ, Cao Q, De Souza AL, VanderWeele DJ, Bryce AH, Kelly WK, et al. Early results from CASCARA: A phase 2 study of cabazitaxel/carboplatin plus abiraterone in high-volume metastatic castrate-sensitive prostate cancer (mCSPC). Journal of Clinical Oncology. 2023;41(16_suppl):5071–5071.
Schaeffer EM, Lurie RH, Adra N, An Y, Bitting R, Chapin B, et al. NCCN Guidelines Version 3.2024 Prostate Cancer [Internet]. 2024. Available from: https://www.nccn. org/home/
Lowrance W, Breau R, Chou R, Chapin BF, Crispino T, Dreicer R, et al. ADVANCED PROSTATE CANCER: AUA/SUO GUIDELINE EARLY EVALUATION AND COUNSELING. 2023.
Parker C, Castro E, Fizazi K, Heidenreich A, Ost P, Procopio G, et al. Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†. Annals of Oncology. 2020;31(9):1119–34.
EAU-EANM-ESTRO-ESUR-ISUP-SIOG-Guidelines-on-Prostate-Cancer-2024_2024-04-09-132035_ypmy_2024-04-16-122605_lqpk.
Gravis G, Fizazi K, Joly F, Oudard S, Priou F, Esterni B, et al. Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUGAFU 15): a randomised, open-label, phase 3 trial. Lancet Oncol. 2013;14(2):149–58.
onix_3.0::thoth | Thoth ONIX 3.0 |
---|---|
onix_3.0::project_muse | Project MUSE ONIX 3.0 |
onix_3.0::oapen | OAPEN ONIX 3.0 |
onix_3.0::jstor | JSTOR ONIX 3.0 |
onix_3.0::google_books | Google Books ONIX 3.0 |
onix_3.0::overdrive | OverDrive ONIX 3.0 |
onix_2.1::ebsco_host | EBSCO Host ONIX 2.1 |
csv::thoth | Thoth CSV |
json::thoth | Thoth JSON |
kbart::oclc | OCLC KBART |
bibtex::thoth | Thoth BibTeX |
doideposit::crossref | CrossRef DOI deposit |
onix_2.1::proquest_ebrary | ProQuest Ebrary ONIX 2.1 |
marc21record::thoth | Thoth MARC 21 Record |
marc21markup::thoth | Thoth MARC 21 Markup |
marc21xml::thoth | Thoth MARC 21 XML |